A Comparative Study Between Single Dose & Multiple Doses of Mitomycin-C in the Management of Transitional Cell Carcinoma of Urinary Bladder

Objectives: To find out the efficacy of post TURBT immediate single dose adjuvant intravesical Mitomycin C therapy in comparison with multi-dose regimen of Mitomycin C therapy in the management of superficial transitional cell carcinoma of the urinary bladder. Methods: Total 76 patients of bladder mass were included in the study who had undergone transurethral resection followed by immediate single instillation of Mitomycin C. After availability of histopathological examination report of resected tumor, those fulfill the selection criteria were randomized into two groups. One group (Group A) was the odd numbers of the patients who already received immediate single intravesical instillation of Mitomycin C and another group (Group B) even number of the patients who received single dose of intravesical instillation of Mitomycin C immediately with additional 5 instillations (1 week interval for 5 weeks) and in whom prospective follow-up could be completed within next 12 months Results: The effect of single intravesical instillation of 40 mg of Mitomycin C (Group A) within 24 hours of TURBT with that of multiple doses (six doses) of Mitomycin C (Group B) in similar dose was insignificant. Conclusion: The efficacy of MMC single dose was similar to MMC multi-dose regimen with insignificant difference of side effect among the two groups (0% versus 6.25%). Bangladesh Journal of Urology, Vol. 20, No. 2, July 2017 p.74-77

Download Full-text

Adjuvant Intravesical Chemotherapy in the Management of Superficial Transitional Cell Carcinoma of Urinary Bladder Following Transurethral Resection of Bladder Tumor- Result of Single Dose and Multiple doses of Mitomycin C

Bangladesh Journal of Urology ◽

10.3329/bju.v23i1.50292 ◽

2020 ◽

Vol 23 (1) ◽

pp. 62-66

Author(s):

Shahriar Md Kabir Hasan ◽

Kazi Rafiqul Abedin ◽

Md Shawkat Alam ◽

Anup Roy Chowdhury ◽

Md Moynul Hoque Chowdhury ◽

...

Keyword(s):

Bladder Cancer ◽

Single Dose ◽

Urinary Bladder ◽

Transitional Cell Carcinoma ◽

Mitomycin C ◽

Dose Group ◽

Transitional Cell ◽

Group A ◽

Group B

Background: Bladder cancer is the second most common cancer of the genitourinary tract. Mitomycin C has been commonly used in a perioperative fashion delivered intravesically immediately after TURBT Objective: To compare the results of post TURBT immediate single dose and multidose regimen of Mitomycin C therapy in the management of superficial transitional cell carcinoma of the urinary bladder. Method: The present prospective and comparative interventional study was conducted in the Department of Urology, National Institute of Kidney Diseases and Urology, Sher-E-Bangla Nagar, Dhaka from January 2015 to December 2016. Patients of superficial bladder cancer (tumor size ≤3 cm, number ≤3, grade I, II) were randomly included in the 2 groups. The sample size was seventy four (74). Thirty (30) patients were in each group and fourteen (14) were excluded from the study. In MMC single dose group (Group A), single dose of MMC 40mg/ 40ml was started immediately within 24 hours of TURBT. In MMC multi-dose group (Group B) 1st instillation of chemotherapy was started immediately within 24 hours of TURBT and additional instillation (5 instillations) were given as OPD basis and was continued weekly for 5 weeks. Follow-up was done on 3rd, 6th, 12th month of initial TURBT. Results: In this study mean age was 61.8±13.7 years in group A and 62.7±13.6 years in group B. Male was found 25 (83.3%) in group A and 26 (86.7%) in group B. Female was found 5 (16.7%) in group A and 4 (13.3%) in group B. Mean size of the tumor was found 2.13±0.78 cm in group A and 2.05±0.84 cm in group B. Mean number of tumor was found 1.8±0.8 in group A and 1.9±0.7 in group B. Tumor grade I was found 23 (76.7%) in group A and 25 (83.3%) in group B. Tumor status Ta of superficial bladder was found 25 (83.3%) in group A and 26 (86.7%) group B. Tumor status T1 of superficial bladder was found 5(16.7%) in group A and 4 (13.3%) group B. Five (16.7%) patients was found recurred in group A and 4 (13.3%) in group B at 6th month follow up. At 12th month follow up, 6 (20.0%) patients was found recurred in group A and 5 (16.7%) in group B. Side effect was found in 2 (6.7%) patients in group B and not found in group A. Conclusion: MMC single dose was similar to MMC multi-dose regimen with insignificant difference among the two. Bangladesh Journal of Urology, Vol. 23, No. 1, January 2020 p.62-66

Download Full-text

Faculty Opinions recommendation of Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)--avoidance, recognition, management and consent.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718367739.793494848 ◽

2014 ◽

Author(s):

Asif Muneer ◽

Vaibhav Modgil

Keyword(s):

Single Dose ◽

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Mitomycin C ◽

Transitional Cell

Download Full-text

Mitomycin c in the treatment of metastatic transitional cell carcinoma of urinary bladder

Cancer ◽

10.1002/1097-0142(197305)31:5<1150::aid-cncr2820310516>3.0.co;2-q ◽

1973 ◽

Vol 31 (5) ◽

pp. 1150-1153 ◽

Cited By ~ 22

Author(s):

K. Early ◽

E. G. Elias ◽

A. Mittelman ◽

D. Albert ◽

G. P. Murphy

Keyword(s):

Urinary Bladder ◽

Transitional Cell Carcinoma ◽

Cell Carcinoma ◽

Mitomycin C ◽

Transitional Cell

Download Full-text

Carcinoma of the unrivaled bilharzial urinary bladder of Egyptians: Expanding radiotherapy and decline of obligate cystectomy—Historic perspective and a demonstration study of 34 patients.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e15571 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e15571-e15571

Author(s):

Gamal Moustafa Saied ◽

Karim G Moustafa

Keyword(s):

Bladder Cancer ◽

Urinary Bladder ◽

Cell Carcinoma ◽

Transurethral Resection ◽

Transitional Cell ◽

Treatment Modalities ◽

Clinicopathological Findings ◽

Egyptian Patients ◽

Group A ◽

Group B

e15571 Background: The objective is to validate the new clinicopathological features involving carcinoma of the unrivaled urinary bladder of Egyptian patients, alongside studying their reflection on management. Methods: Timely contributions of leading Egyptian experts in bladder cancer in the last 4 decades were reviewed. Additionally, 34 patients were studied in 2 subsets based on planned treatment modality: group A (12 cases) treated by cystectomy and group B (22 cases) treated by transurethral resection plus stipulated radiotherapy. Treatment results were evaluated. Results: An overview of studies published in the last 4 decades is given, demonstrating a striking change in the characteristic features of bladder carcinoma in this country, more obvious in 2007 and after. Present work revealed 44.1% of patients had their tumor erupting in a bilharzial bladder where walls demonstrated classical cystoscopic features of the disease. Histologically 86.7 % of them were squamous cell carcinoma. Almost 60% of patients had had their tumors in a non-bilharzial bladder, 94.7% of them were transitional cell carcinoma. Thirteen out of 15 patients in group A were treated by cystectomy carrying 7.7 % perioperative mortality, whereas 11 out of 12 patients in group B received radiotherapy preceded by transurethral resection. Distribution of clinicopathological findings and treatment modalities is tabulated. Conclusions: Bladder cancer in Egyptian patients has lost its weird features imposed by bilharzial cystitis. It is shifting towards alien types making it suitable for organ preserving management.

Download Full-text